BriaCell Therapeutics Corp.
BCTX
$4.52
$0.214.87%
NASDAQ
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -7.22M | -8.20M | -8.09M | -6.13M | -6.29M |
| Total Depreciation and Amortization | 26.70K | 26.70K | 26.70K | 26.70K | 26.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 150.50K | 238.50K | -474.20K | 13.70K | -525.60K |
| Change in Net Operating Assets | -922.60K | 227.60K | 406.40K | -1.08M | 870.10K |
| Cash from Operations | -7.97M | -7.70M | -8.13M | -7.16M | -5.92M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 7.28M | -75.00K | -7.39M | -105.00K | -75.00K |
| Cash from Investing | 7.28M | -75.00K | -7.39M | -105.00K | -75.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 27.87M | -- | 13.56M | 14.71M | 5.22M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 27.87M | -- | 13.56M | 14.71M | 5.22M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 27.19M | -7.78M | -1.97M | 7.45M | -778.60K |